-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

661. Malignant Stem and Progenitor Cells: Poster III

Malignant Stem and Progenitor Cells Program: Oral and Poster Abstracts
Type: Poster
Monday, December 7, 2015: 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Tzu-Chieh Ho, PhD1*, Craig T Jordan, PhD2, Mark W. LaMere, BA3*, John M. Ashton, PhD3*, Kristen O'Dwyer, MD3*, Jason H. Mendler, MD, PhD4, Jane L. Liesveld, MD5, Eunice S. Wang, MD6, Monica L. Guzman, PhD7, Laura M. Calvi, MD3 and Michael W. Becker, MD3

1Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, NY
2Division of Hematology, University of Colorado School of Medicine, Aurora, CO
3James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
4J.P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
5James P. Wilmot Cancer Institute, Department of Medicine, University of Rochester Medical Center, Rochester, NY
6Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
7Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY

Heather Duncan, MSc1*, Karin G. Hermans, PhD2*, Sara Chisling3*, Isabelle Laverdiere, B.Pharm, PhD4*, Mark D. Minden, MD, PhD5, John E. Dick, PhD5 and Kolja Eppert, PhD4

1Division of Experimental Medicine, McGill University, Montreal, QC, Canada
2Program of Developmental and Stem Cell Biology, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
3Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
4Department of Pediatrics, McGill University, Montreal, QC, Canada
5Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Heather A Himburg, PhD1*, Liman Zhao1* and John P Chute, MD1,2,3

1Division of Hematology/Oncology, Department of Medicine, UCLA, Los Angeles, CA
2CA Broad Center for Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, CA
3Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA

Nesrine Aroua, PhD1*, Jean-Emmanuel Sarry, PhD2*, Fabienne De Toni, PhD3*, Robin Carson, MD, BA4, Francois Vergez, VD PhD5*, Estelle Saland2*, Mayumi Sugita, MD6*, Martin Carroll, MD7, Christian Recher, MD-Ph.D.8 and Gwenn Danet, PhD9*

1INSERM, CRCT-U1037, Toulouse, France
2INSERM, CRCT, Toulouse, France
3CRCT, INSERM, Toulouse, France
4Janssen Research & Development, Spring House, PA
5Institut Universitaire du Cancer, Toulouse, France
6Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
7Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
8Institut Universitaire du Cancer de Toulouse, Toulouse, France
9Univ. of Chicago Medical Center, Chicago, IL

Stacy W. Blain, Ph.D.1*, Danielle Joseph2* and Amitabha Mazumder, M.D.3,4

1Pediatrics and Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY
2SUNY Downstate Medical Center, Brooklyn
3Medicine, NYU Perlmutter Cancer Center, NY, New York, NY
4Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY

*signifies non-member of ASH